- Development and Implementation of an Aluminum-Promoted Phosphorylation in the Uprifosbuvir Manufacturing Route
-
A novel application of the synthesis of pronucleotide (ProTide) 5′-phosphoramidate monoesters promoted by aluminum-based Lewis acids is described. In the multikilogram synthesis of uprifosbuvir (MK-3682, 1), a clinical candidate for the treatment of hepatitis C, this methodology provided >100:1 diastereoselectivity at the phosphorus stereocenter and >100:1 selectivity for the 5′-mono phosphorylation over undesired bisphosphorylation side products. The high diastereoselectivity and mono/bis ratio achieved enabled elimination of the tedious workup associated with the tert-butyl magnesium chloride protocol commonly used to install this functionality in similar nucleotide prodrugs, achieving a near doubling of the isolated yield from 45% to 81%. The process development and purity control strategy of MK-3682, as well as handling of the pyrophoric reagent on scale, will also be discussed.
- Liu, Zhuqing,Klapars, Artis,Simmons, Bryon,Bellomo, Ana,Kalinin, Alexei,Weisel, Mark,Hill, Jerry,Silverman, Steven M.
-
p. 661 - 667
(2020/12/21)
-
- Synthesis and evaluation of 2′-dihalo ribonucleotide prodrugs with activity against hepatitis C virus
-
[Figure presented] Hepatitis C virus (HCV) nucleoside inhibitors have been a key focus of nearly 2 decades of HCV drug research due to a high barrier to drug resistance and pan-genotypic activity profile provided by molecules in this drug class. Our investigations focused on several potent 2′-halogenated uridine-based HCV polymerase inhibitors, resulting in the discovery of novel 2′-deoxy-2′-dihalo-uridine analogs that are potent inhibitors in replicon assays for all genotypes. Further studies to improve in vivo performance of these nucleoside inhibitors identified aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs 18a and 18c, which provide high levels of the active triphosphate in dog liver. AIBEE prodrug 18c was compared with sofosbuvir (1) by co-dosing both compounds by oral administration in dog (5 mg/kg each) and measuring liver concentrations of the active triphosphate metabolite at both 4 and 24 h post dosing. In this study, 18c provided liver triphosphate concentrations that were 6-fold higher than sofosbuvir (1) at both biopsy time points, suggesting that 18c could be a highly effective agent for treating HCV infected patients in the clinic.
- Chris Krueger,Chen, Hui-Ju,Randolph, John T.,Brown, Brian S.,Halvorsen, Geoff T.,Heyman, Howard R.,Li, Tongmei,Marvin, Christopher C.,Shanley, Jason P.,Voight, Eric A.,Bow, Daniel A.J.,Van Handel, Cecilia,Peterkin, Vincent,Carr, Robert A.,Stolarik, DeAnne,Dekhtyar, Tatyana,Irvin, Michelle L.,Krishnan, Preethi,Henry, Rodger F.,Wagner, Rolf,DeGoey, David A.
-
-
- Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection
-
We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.
- Wang, Guangyi,Dyatkina, Natalia,Prhavc, Marija,Williams, Caroline,Serebryany, Vladimir,Hu, Yujian,Huang, Yongfei,Wan, Jinqiao,Wu, Xiangyang,Deval, Jerome,Fung, Amy,Jin, Zhinan,Tan, Hua,Shaw, Kenneth,Kang, Hyunsoon,Zhang, Qingling,Tam, Yuen,Stoycheva, Antitsa,Jekle, Andreas,Smith, David B.,Beigelman, Leonid
-
p. 4555 - 4570
(2019/05/17)
-
- New reactions and processes for the efficient synthesis of a HCV NS5b prodrug
-
Herein we describe the route scouting and process development efforts toward a green and sustainable synthesis of the HCV NS5b cyclic prodrug nucleoside (CPN) 1. Through the discovery and development of a crystallization-induced dynamic resolution and a n
- Orr, Robert K.,Dunn, Jamie M. McCabe,Nolting, Andrew,Hyde, Alan M.,Ashley, Eric R.,Leone, Joseph,Sirota, Eric,Jurica, Jon A.,Gibson, Andrew,Wise, Christopher,Oliver, Steven,Ruck, Rebecca T.
-
p. 2519 - 2525
(2018/06/11)
-
- A multifunctional catalyst that stereoselectively assembles prodrugs
-
The catalytic stereoselective synthesis of compounds with chiral phosphorus centers remains an unsolved problem. State-of-the-art methods rely on resolution or stoichiometric chiral auxiliaries. Phosphoramidate prodrugs are a critical component of pronucleotide (ProTide) therapies used in the treatment of viral disease and cancer. Here we describe the development of a catalytic stereoselective method for the installation of phosphorusstereogenic phosphoramidates to nucleosides through a dynamic stereoselective process. Detailed mechanistic studies and computational modeling led to the rational design of a multifunctional catalyst that enables stereoselectivity as high as 99:1.
- DiRocco, Daniel A.,Ji, Yining,Sherer, Edward C.,Klapars, Artis,Reibarkh, Mikhail,Dropinski, James,Mathew, Rose,Maligres, Peter,Hyde, Alan M.,Limanto, John,Brunskill, Andrew,Ruck, Rebecca T.,Campeau, Louis-Charles,Davies, Ian W.
-
p. 426 - 430
(2017/05/04)
-
- The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2′-α-chloro-2′-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors
-
Herein we describe the discovery of IDX21437 35b, a novel RP D-aminoacid-based phosphoramidate prodrug of 2′-α-chloro-2′-β-C-methyluridine monophosphate. Its corresponding triphosphate 6 is a potent inhibitor of the HCV NS5B RNA-dependent RNA polymerase (RdRp). Despite showing very weak activity in the in vitro Huh-7 cell based HCV replicon assay, 35b demonstrated high levels of active triphosphate 6 in mouse liver and human hepatocytes. A biochemical study revealed that the metabolism of 35b was mainly attributed to carboxyesterase 1 (CES1), an enzyme which is underexpressed in HCV Huh-7-derived replicon cells. Furthermore, due to its metabolic activation, 35b was efficiently processed in liver cells compared to other cell types, including human cardiomyocytes. The selected RP diastereoisomeric configuration of 35b was assigned by X-ray structural determination. 35b is currently in Phase II clinical trials for the treatment of HCV infection.
- Alexandre, Fran?ois-René,Badaroux, Eric,Bilello, John P.,Bot, Stéphanie,Bouisset, Tony,Brandt, Guillaume,Cappelle, Sylvie,Chapron, Christopher,Chaves, Dominique,Convard, Thierry,Counor, Clément,Da Costa, Daniel,Dukhan, David,Gay, Marion,Gosselin, Gilles,Griffon, Jean-Fran?ois,Gupta, Kusum,Hernandez-Santiago, Brenda,La Colla, Massimiliano,Lioure, Marie-Pierre,Milhau, Julien,Paparin, Jean-Laurent,Peyronnet, Jér?me,Parsy, Christophe,Pierra Rouvière, Claire,Rahali, Houcine,Rahali, Rachid,Salanson, Aurélien,Seifer, Maria,Serra, Ilaria,Standring, David,Surleraux, Dominique,Dousson, Cyril B.
-
p. 4323 - 4330
(2017/09/12)
-
- PROCESS FOR MAKING CHLORO-SUBSTITUTED NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS
-
The present invention is directed to a process for making Chloro-Substituted Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
- -
-
Paragraph 0250; 0251; 0252; 0253; 0256; 0257
(2017/09/02)
-
- Antiviral nucleoside phosphoramidate and pharmaceutical composition and applications thereof
-
The invention provides an antiviral nucleoside phosphoramidate and a pharmaceutical composition and applications thereof. The nucleoside phosphoramidate compound is prepared by connecting nucleoside with phosphate through phosphorus-oxygen bonds. The structural formulas of the nucleoside phosphoramidate compound are represented by a, a1, a2, b, b1, and b2. The invention also discloses stereoisomers, pharmaceutically acceptable salts, hydrates, solvates, or crystals of the nucleoside phosphoramidate compound. The anti-hepatitis C activity of the provided novel nucleoside phosphoramidate is obviously better than that of sofosbuvir used in clinic. On the saccharide ring, the fluorine atoms are replaced by chlorine atoms, and the cytotoxicity of measure cell lines is prominently reduced. By systematically modifying and optimizing the basic groups, saccharide rings, and prodrugs, the anti-hepatitis C activity of partial synthesized compounds is 2 to 10 times higher than that of sofosbuvir. At the same time, the key parts of metabolism are optimized, the metabolism stability and chemical stability of synthesized compounds in plasma are better, compared with those of sofosbuvir.
- -
-
-
- PROCESS FOR MAKING NUCLEOSIDE PHOSPHORAMIDATE COMPOUNDS
-
The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
- -
-
-